Insight Molecular Diagnostics Inc.
NASDAQ:IMDXMedical - Diagnostics & Research
+$0.13 today
- Market cap
- $52.08M
- Beta
- 1.79
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.39
Volume 0.64M
Average 0.38M
IMDX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Insight Molecular Diagnostics Inc.NASDAQ: IMDX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of $24.7M fell 13.5% year over year, ahead of the -50.6% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at -7.8% a year.
Context
- Financing cash flow amounted to 692.3% of revenue in FY2025, down 393.8 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -13.5% holds above the trailing-twelve-month pace of -50.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 28.07M USD
- Year-over-year change
- +37.4%
- 4-year CAGR
- -22.6%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.07M | +37.4% |
| FY2024 | 2024-12-31 | 20.43M | +67.6% |
| FY2023 | 2023-12-31 | 12.19M | -66.0% |
| FY2022 | 2022-12-31 | 35.81M | -54.3% |
| FY2021 | 2021-12-31 | 78.36M | — |
Financing Cash Flow vs competitors
How IMDX compares with its peers on the latest reported figures
- IMDX's LTM Mar 2026 financing cash flow of $24.21M is the 9th largest of the 10 companies compared; the peer median is $89.31M.
- Its year-over-year change of -50.6% is the lowest of 10, against a peer median of +1085.3%.
- Financing cash flow amounts to 1242.3% of revenue for IMDX, versus a peer median of 311.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $215.52M | +89700.8% | +652.5% | 385.8% | |
| LTM Mar 2026 | $180.48M | +300903.0% | +202.6% | 10116.9% | |
| LTM Mar 2026 | $126.91M | +1085.3% | +379.4% | 364.0% | |
| LTM Mar 2026 | $109.5M | +6044.6% | -1.3% | — | |
| LTM Mar 2026 | $89.31M | +520.7% | -5.8% | 258.5% | |
| LTM Mar 2026 | $27.87M | +110.1% | -36.8% | 96.4% | |
| LTM Mar 2026 | $26.83M | -17.0% | — | 34.4% | |
| LTM Mar 2026 | $24.66M | +9371.4% | +212.3% | 147.5% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $24.21M | -50.6% | -7.8% | 1242.3% |
| LTM Mar 2026 | $16.27M | +62.5% | -16.5% | 549.9% | |
| Peer median (excluding IMDX) | $89.31M | +1085.3% | +100.6% | 311.2% | |
Competitors are the stored peer set for IMDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (64.1M) | (72.9M) | (27.78M) | (60.66M) | (50.22M) |
| Depreciation & Amortization | 4.21M | 5.22M | 1.68M | 1.56M | 2.2M |
| Deferred Income Tax | (9.26M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.84M | 10.04M | 6.57M | 1.91M | 2.22M |
| Change in Working Capital | 149K | (1.94M) | (3.97M) | (1.32M) | 2.73M |
| Accounts Receivables | (1.23M) | (575K) | 109K | (1.13M) | 485K |
| Inventory | 0 | 0 | 0 | (410K) | (36K) |
| Accounts Payables | (1.35M) | 297K | (4.76M) | 967K | 2.65M |
| Other Working Capital | 2.73M | (1.66M) | 677K | (749K) | (368K) |
| Other Non-Cash Items | 26.22M | 14.01M | 174K | 37.79M | 20.9M |
| Operating Cash Flow | (35.94M) | (45.57M) | (23.33M) | (20.71M) | (22.18M) |
| Capital Expenditures | (2.25M) | (4.34M) | (281K) | (516K) | (3.19M) |
| Acquisitions (Net) | (11.71M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 367K | 0 | 0 |
| Other Investing Activities | 0 | 0 | (1.02M) | 4K | 0 |
| Investing Cash Flow | (13.96M) | (4.34M) | (932K) | (512K) | (3.19M) |
| Debt Repayment | (1.53M) | (1.43M) | (117K) | (201K) | (510K) |
| Common Stock Issued | 77.99M | 32.84M | 13.85M | 27.81M | 28.66M |
| Common Stock Repurchased | (239K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.15M | (483K) | (427K) | (1.8M) | (74K) |
| Financing Cash Flow | 78.36M | 35.81M | 12.19M | 20.43M | 28.07M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 973K |
| Net Change in Cash | 28.46M | (14.1M) | (12.07M) | (796K) | 3.68M |
| Free Cash Flow | (38.19M) | (49.91M) | (23.61M) | (21.23M) | (25.37M) |
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
Intrinsic Alpha fair value
Locked
Current Price
$1.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.